Generic name: ketoprofen
Dosage form: Capsules and Extended-Release Capsules
This dosage information does not include all the information needed to use Orudis safely and effectively. See full prescribing information for Orudis.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Rheumatoid Arthritis and Osteoarthritis
Carefully consider the potential benefits and risks of Orudis and Oruvail and other treatment options before deciding to use Orudis and Oruvail. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
After observing the response to initial therapy with Orudis and Oruvail, the dose and frequency should be adjusted to suit an individual patient's needs.
The recommended starting dose of ketoprofen in otherwise healthy patients is for Orudis 75 mg three times or 50 mg four times a day, or for Oruvail 200 mg administered once a day. Smaller doses of Orudis or Oruvail should be utilized initially in small individuals or in debilitated or elderly patients. The recommended maximum daily dose of ketoprofen is 300 mg/day for Orudis or 200 mg/day for Oruvail (see “INDIVIDUALIZATION OF DOSAGE”).
Dosages higher than 300 mg/day of Orudis or 200 mg/day of Oruvail are not recommended because they have not been studied. Concomitant use of Orudis and Oruvail is not recommended. Relatively smaller people may need smaller doses (see “INDIVIDUALIZATION OF DOSAGE”).
Management of Pain and Dysmenorrhea
The usual dose of Orudis recommended for mild-to-moderate pain and dysmenorrhea is 25 to 50 mg every 6 to 8 hours as necessary. A smaller dose should be utilized initially in small individuals, in debilitated or elderly patients, or in patients with renal or liver disease (see ““PRECAUTIONS”). A larger dose may be tried if the patient's response to a previous dose was less than satisfactory, but doses above 75 mg have not been shown to give added analgesia. Daily doses above 300 mg are not recommended because they have not been adequately studied. Because of its typical nonsteroidal anti-inflammatory drug-side-effect profile, including as its principal adverse effect GI side effects (see “WARNINGS” and “ADVERSE REACTIONS”), higher doses of Orudis should be used with caution and patients receiving them observed carefully (see “INDIVIDUALIZATION OF DOSAGE”).
Oruvail is not recommended for use in treating acute pain because of its extended-release characteristics.